Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 1;322(1):1-7.
doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11.

Ovarian cancer stem cell markers: prognostic and therapeutic implications

Daniela Burgos-Ojeda  1 , Bo R Rueda, Ronald J Buckanovich
Affiliations
Review

Ovarian cancer stem cell markers: prognostic and therapeutic implications

Daniela Burgos-Ojeda et al. Cancer Lett. .

Abstract

Cancer stem cells are rare chemotherapy resistant cells within a tumor which can serve to populate the bulk of a tumor with more differentiated daughter cells and potentially contribute to recurrent disease. Ovarian cancer is a disease for which at the time of initial treatment we can obtain complete clinical remission in the majority of patients. Unfortunately, most will relapse and succumb to their disease. This clinical course is in line with the cancer stem cell model. In the past 5 years a significant amount of work has been done to identify cells with characteristics of ovarian cancer stem cells. This review will focus specifically on the markers used to define human ovarian cancer stem cells, the prognostic implications of the expression of these cancer stem cell markers in patient's primary tumors, and the potential of these cancer stem cell markers to serve as therapeutic targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Proposed hierarchy of ovarian cancer stem cell differentiation based on the current literature
A rare common ovarian CSC, for which markers have yet to be defined can give rise to either an ALDH+CD133+ early progenitor or a CD44+CD117+ early progenitor. Each of which can subsequently divide into more differentiated progenitors. The potential for expression of CD24 and CD44 in both lineages is indicated by the colored bars. Rounded arrows indicate cells with self-renewal capacity which have the potential to serve as CSC. Small arrows indicate the unproven potential for 'de-differentiation'.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Medema JP, Vermeulen L. Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. Nature. 2011;474:318–326. - PubMed
    1. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells--old concepts, new insights. Cell Death Differ. 2008;15:947–958. - PubMed
    1. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991–4001. - PMC - PubMed
    1. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209–218. - PubMed
    1. Landen CN, Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Jr, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9:3186–3199. - PMC - PubMed